{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:36:34Z","timestamp":1784291794515,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Soonchunhyang University Research Fund"},{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Soonchunhyang University Bucheon Hospital Hyangseol Research Fund 2023"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jhepr.2025.101489","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T02:48:23Z","timestamp":1750474103000},"page":"101489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort"],"prefix":"10.1016","volume":"7","author":[{"given":"Yoon E.","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9628-421X","authenticated-orcid":false,"given":"Jae Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-3623","authenticated-orcid":false,"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101489_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4254\/wjh.v9.i1.48","article-title":"Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience","volume":"9","author":"Lovett","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3350\/cmh.2021.0179","article-title":"Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3350\/cmh.2014.20.3.261","article-title":"Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-na\u00efve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort","volume":"20","author":"Ahn","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2025.101489_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-019-00474-1","article-title":"Bone update: is it still an issue without tenofovir disoproxil fumarate?","volume":"17","author":"Shiau","year":"2020","journal-title":"Curr Hiv\/aids Rep"},{"key":"10.1016\/j.jhepr.2025.101489_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijid.2022.09.021","article-title":"Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"124","author":"Yang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhepr.2025.101489_bib7","first-page":"41","article-title":"Tenofovir-associated bone density loss","volume":"6","author":"Grigsby","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jhepr.2025.101489_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1097\/QAD.0000000000000760","article-title":"Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients","volume":"29","author":"Hamzah","year":"2015","journal-title":"Aids"},{"key":"10.1016\/j.jhepr.2025.101489_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020146","article-title":"Effects of tenofovir disoproxil fumarate on bone quality beyond bone density-A scoping review of the literature","volume":"17","author":"Hashwin Singh","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhepr.2025.101489_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jgh.16593","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B","volume":"39","author":"Nam","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2025.101489_bib12","first-page":"146","article-title":"A real-world study on safety and efficacy of TAF treatment in HBV patients with high risk of osteoporosis or osteopenia in China","volume":"30","author":"Li","year":"2024","journal-title":"Altern Ther Health Med"},{"key":"10.1016\/j.jhepr.2025.101489_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101489_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hiv.12123","article-title":"Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks","volume":"15","author":"Bloch","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.jhepr.2025.101489_bib16","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1093\/jac\/dku300","article-title":"Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study)","volume":"69","author":"Negredo","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhepr.2025.101489_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5152\/tjg.2020.18024","article-title":"Effects of long-term tenofovir and entecavir treatment on bone mineral density in patients with chronic hepatitis B","volume":"33","author":"Kahraman","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101489_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jhep.2023.12.001","article-title":"Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B","volume":"80","author":"Yip","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101489_bib19","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1002\/sim.6977","article-title":"Robust empirical calibration of p-values using observational data","volume":"35","author":"Schuemie","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2025.101489_bib20","series-title":"Reimbursement guideline for osteoporosis treatment","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101489_bib21","article-title":"Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross-sectional study","volume":"6","author":"Bukhari","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.jhepr.2025.101489_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:55:58Z","timestamp":1757094958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2589555925001673"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101489","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101489"}}